Search

Displaying results 4121 - 4130 of 10000 in total
  1. Drug

    99mTc-glucarate

    go.drugbank.com/drugs/DB05810
    Investigational

    99mTc-glucarate(GLA) is an agent for non-invasive detection of breast tumours.

  2. Drug

    Glimepiride

    go.drugbank.com/drugs/DB00222
    ApprovedInvestigational

    Compared to [glipizide], another second SU drug, glimepiride has a longer duration of action. … Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular

    Mixtures: AMARYL®M 1 MG/ 500 MG, AMARYL®M 4 MG/ 1000 MGCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  3. Drug

    Danazol

    go.drugbank.com/drugs/DB01406
    ApprovedInvestigational

    A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsProducts: CIPLADANOGEN® 200 MG CAPSULAS
  4. Drug

    Glycol salicylate

    go.drugbank.com/drugs/DB11323
    Approved

    Glycol salicylate (GS), composed of salicylic acid (SA) and ethylene glycol, is a non-steroidal anti-inflammatory drug [L2687]. … Glycol salicylate, also known as _2-hydroxyethyl salicylate_, is a benzoate ester formed from the condensation of the carboxy group of salicylic acid with one of the hydroxy groups of ethylene glycol.

    Synonyms: 2-hydroxyethyl 2-oxidanylbenzoate, 2-hydroxybenzoic acid 2-hydroxyethyl ester
  5. Drug

    R450

    go.drugbank.com/drugs/DB05469
    Experimental

    R450 is an alpha 1 antagonist that acts to tighten the muscle tone in the bladder. It is being considered for treatment of stress-related urinary incontinence.

  6. Drug

    Fosdenopterin

    go.drugbank.com/drugs/DB16628
    Approved

    In 2009 a recombinant, E. coli-produced cPMP was granted orphan drug designation by the FDA, becoming the first therapeutic option for patients with MoCD type A. … [A230088] Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity.

    Synonyms: C(PMP)Categories: MATE 1 Substrates, MATE 2 Inhibitors
  7. Drug

    EA-2353

    go.drugbank.com/drugs/DB18506
    Investigational

    EA-2353 is a small molecule inhibitor of kinase mediators of the Wnt pathway.

  8. Drug

    DA-6886

    go.drugbank.com/drugs/DB12853
    Investigational

    DA-6886 has been used in trials studying the treatment of Irritable Bowel Syndrome.

    Categories: Heterocyclic Compounds, 1-Ring
  9. Drug

    VX-702

    go.drugbank.com/drugs/DB05470
    Investigational

    In the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA. … VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA). It acts as a p38 MAP kinase inhibitor.

  10. Drug

    Revakinagene taroretcel

    go.drugbank.com/drugs/DB05344
    ApprovedInvestigational

    [A265115] On March 6, 2025, FDA approved revakinagene taroretcel for the treatment of idiopathic macular telangiectasia type 2. … allogeneic encapsulated cell-based gene therapy that contains 200,000 to 440,000 allogeneic retinal pigment epithelial cells expressing recombinant human ciliary neurotropic factor (rhCNTF) (NTC-201-6A

    Synonyms: An allogeneic human adult retinal pigment epithelial (RPE) cell line stably transfected with a plasmid, Allogeneic human adult retinal pigment epithelial (RPE) cell line stably transfected with a plasmid encoding human ciliary neurotrophic factor (CNTF).